Onconetix, Inc. (ONCO) Stock

Onconetix, Inc. (ONCO) is a Healthcare stock trading at $0.65 (as of 2026-08-21), with a market capitalization of $2.56M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Onconetix, Inc. is a biotechnology and pharmaceutical company that commercializes Entadfi, an FDA-approved once-daily oral combination of finasteride and tadalafil for benign prostatic hyperplasia. It is also developing vaccine candidates, including an anti-pneumococcus vaccine and a universal flu vaccine, and it has a licensed virus-like particle platform to develop vaccines for multiple infectious diseases, such as Marburg and monkeypox.

Understand Onconetix, Inc.: how it makes money

Onconetix develops and commercializes biopharmaceutical therapies, it owns Entadfi, an FDA-approved once daily pill for benign prostatic hyperplasia, and it also has vaccine candidates in development, with money expected to come primarily from commercial product sales (and, later, from additional approvals).

The profit model is structurally anchored by ownership of a currently FDA-approved product (Entadfi) for recurring therapy demand, while future upside depends on whether its vaccine candidates successfully advance to approvals and commercialization.

Business quality (Weak): The company has an FDA-approved lead product (Entadfi) plus an ongoing vaccine pipeline, but the latest provided quarter shows negative gross and operating margins, indicating a currently loss-making profile.

Bull case

Entadfi is FDA-approved and is positioned as a once daily pill for treatment of benign prostatic hyperplasia, which supports the idea of an already commercializable therapy: The company owns Entadfi (finasteride and tadalafil), a once daily pill, and states it is FDA-approved.
The pipeline includes vaccine candidates aimed at specific unmet needs in children (infectious middle ear infections) and in the elderly (pneumonia prevention): Onconetix is developing a streptococcus pneumoniae vaccine candidate designed to prevent infectious middle ear infections in children and prevention of pneumonia in the elderly.

Bear case

Near term results appear pressured by loss-making economics, based on the latest provided margin data: For the period ended 2026-03-31, gross margin is shown as -7.7% and operating margin is shown as -47657.2%.
A meaningful portion of long term value is tied to pipeline progress, which introduces regulatory and development uncertainty until approvals occur: Beyond Entadfi, the company is developing vaccine candidates, which implies further steps are required before commercialization.

Valuation — source: SEC EDGAR (first-party)
Price	$0.65
Market Cap	$2.56M
Price / Book	0.19
Price / Sales	7.05

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$815371.00
Net Margin	-1721.0%
Revenue Growth (YoY)	-67.7%
EPS Growth (YoY)	-22.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-9.70 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	CITADEL ADVISORS LLC ($48619.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Karina Fedasz
Employees	12
Country	US
IPO Date	2022-02-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.